|
|
Post by nugjuice on Aug 10, 2015 10:52:40 GMT -5
Nice, they can't borrow the shares in your IRA though. No margin on retirement accounts. Those are nice 'n safe
|
|
|
|
Post by joeypotsandpans on Aug 10, 2015 10:56:31 GMT -5
Matt confirms what I have been saying for months. Print and TV ads are not where it's at. It's online due to the vast majority of people who use the internet to search for info. As for longs lending their shares out to short. I say go for it. At least you'll make some money on the stock. Maybe if the company had its act together, shareholders wouldn't have to lend out their shares in the first place. Online far more targeted and capital efficient especially so for a new product. Not uncommon these days for patient to arrive at physicians office and be handed a tablet to check in or fill out paperwork (digital paperwork that is). In some cases, depending on visit / patient health condition they may see a targeted advertisement on the tablet. Doc gets some $$ for all this so a way for them to generate a bit of revenue and for Rx companies to get their product in front of patient right before they see their physician. Talk about targeting and timing. No TV ads for some time. It just wouldn't be financially prudent. Afrezza needs to have the burden of prior authorization significantly reduced. Interesting comments on the call from an analyst inquiring if MNKD feels impacted by large competitors trying to get exclusive formulary position i.e. big price cut to be only play on formulary. Lots of ways for SNY to effectively work around this. More and better data pertaining to A1c and hypo reductions and then comparing traditional RAA to Afrezza is no longer apples to apples. Mr. Insurance company, my product is priced 25% higher and for that investment, you get patient A1c lowered by XX%, incidences of hypoglycemia lowered by YY%, reduction in ER visits and LT health complications. Mr. Insurance company, the ROI on Afrezza is XXX% so from a pure economic perspective, your and your employer would be adversely impacting shareholder value by not paying a premium for Afrezza. Probably the single biggest factor immediately impacting scripts right now. NVO has no doubt "bought" the insurance companies via the oldest marketing ploy there is with a lesser product, drop/undercut and mass market to try and gain as much market share as possible...this was evident back a while ago when I posted that a hospital pharmacist I know told me they replaced Lantus with Levemir strictly from a cost standpoint. This has been Novo's modus operandi and strategy probably since the Adcom vote...obviously in the last year you've seen the DTC advertising for their "pens", Novolog, and most recently Levemir come out like never seen before. Personally, I think it's flattering that they felt it necessary to take such aggressive measures as obviously it speaks a different tune then the one from the individual that was questioned about Afrezza at the ADA convention. To me it's their swan song, so apropos if you will: en.wikipedia.org/wiki/Swan_song because you better believe those "french" are not going to take it lying down so to speak  Thus, the insulin wars have begun and as Matt stated, "they have some strategic efforts being worked on" when asked about the formulary issues. We all know the inter-relationships that are connected in the investment/government/BP arena and perhaps the longer term investors have battle wounds through an educational process that was incurred via good yet idealistic intentions. I thoroughly admit having paid a tuition for this real world schooling that it has been one helluva an eye opening experience. I also get where Matt is coming from on the shares lent out situation and how that may have impacted his strategies regarding the convertibles over the last couple of quarters. It must have been something for him to see how many in unison were joining in to lend out the shares thus making inventory more widely available. I imagine in the beginning it wasn't playing too big a role but as more and more joined in it must of most certainly caused some consternation on managements part when looking to implement different strategies for retiring the convertible. Bottom line the CC confirmed what my conversations have been with the SNY rep. and that is they continue to have a methodical plan in place both in dealing with the formulary issues and concurrently working within the medical professional arena to establish Afrezza for what it is and now has been endorsed by most of those using it... as a second to none best in class RAA insulin. I hear the swan song loud and clear and looking forward to the swan resting in peace as I smile now when I see those ads touting the inferior product |
|
|
|
Post by newmnkdinvestor on Aug 10, 2015 10:56:40 GMT -5
I sold my IRA position I bought on Friday this morning. I had this strange feeling the stock would come back down. I thought the CC went well but not reason for the large pop. If anything Techno sphere is eons away. This is the Afrezza show for the extended future.
|
|
|
|
Post by newmnkdinvestor on Aug 10, 2015 10:57:49 GMT -5
Nice, they can't borrow the shares in your IRA though. No margin on retirement accounts. Those are nice 'n safe You are correct. I made sure of this on Fidleity. They have limited margin so that you can avoid the settled cash dates but you cannot borrow more then what the account has available |
|
|
|
Post by newmnkdinvestor on Aug 10, 2015 11:02:37 GMT -5
If you have a Margin account you can still designate that your MannKind shares be held in a cash position and they should not be lent out. hmmm, I dont follow that. I thought margin is only added to a cash account as a perq for working with that broker. However the perq they receive is getting to lend out your shares and collect interest. In my cash account the amount I am able to margin is based on the value of my cash account. Your way sounds too good to be true. I just dont see why they would let you use their money and then let you avoid the shares being lent out. Essentially you could lend out your margined shares. |
|
|
|
Post by newmnkdinvestor on Aug 10, 2015 11:05:57 GMT -5
Matt put to rest the FUD being spread on DaZoo (and briefly discussed here) that management is lending out shares, stating that MannKind employees are not allowed to keep their shares in any account that permits lending. Thanks for clearing that up, Matt! Employees. Is Al Mann considered an employee? Does he fall under that? I am a cynic so I was thinking both ways about the comment |
|
|
|
Post by jay1ajay1a on Aug 10, 2015 11:06:20 GMT -5
I have never lent any of my shares, most of my shares are in four different IRAs and a small holding in my brokerage account.
I could not be happier with the CC.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 10, 2015 11:23:16 GMT -5
Online far more targeted and capital efficient especially so for a new product. Not uncommon these days for patient to arrive at physicians office and be handed a tablet to check in or fill out paperwork (digital paperwork that is). In some cases, depending on visit / patient health condition they may see a targeted advertisement on the tablet. Doc gets some $$ for all this so a way for them to generate a bit of revenue and for Rx companies to get their product in front of patient right before they see their physician. Talk about targeting and timing. No TV ads for some time. It just wouldn't be financially prudent. Afrezza needs to have the burden of prior authorization significantly reduced. Interesting comments on the call from an analyst inquiring if MNKD feels impacted by large competitors trying to get exclusive formulary position i.e. big price cut to be only play on formulary. Lots of ways for SNY to effectively work around this. More and better data pertaining to A1c and hypo reductions and then comparing traditional RAA to Afrezza is no longer apples to apples. Mr. Insurance company, my product is priced 25% higher and for that investment, you get patient A1c lowered by XX%, incidences of hypoglycemia lowered by YY%, reduction in ER visits and LT health complications. Mr. Insurance company, the ROI on Afrezza is XXX% so from a pure economic perspective, your and your employer would be adversely impacting shareholder value by not paying a premium for Afrezza. Probably the single biggest factor immediately impacting scripts right now. NVO has no doubt "bought" the insurance companies via the oldest marketing ploy there is with a lesser product, drop/undercut and mass market to try and gain as much market share as possible...this was evident back a while ago when I posted that a hospital pharmacist I know told me they replaced Lantus with Levemir strictly from a cost standpoint. This has been Novo's modus operandi and strategy probably since the Adcom vote...obviously in the last year you've seen the DTC advertising for their "pens", Novolog, and most recently Levemir come out like never seen before. Personally, I think it's flattering that they felt it necessary to take such aggressive measures as obviously it speaks a different tune then the one from the individual that was questioned about Afrezza at the ADA convention. To me it's their swan song, so apropos if you will: en.wikipedia.org/wiki/Swan_song because you better believe those "french" are not going to take it lying down so to speak ;) Thus, the insulin wars have begun and as Matt stated, "they have some strategic efforts being worked on" when asked about the formulary issues. We all know the inter-relationships that are connected in the investment/government/BP arena and perhaps the longer term investors have battle wounds through an educational process that was incurred via good yet idealistic intentions. I thoroughly admit having paid a tuition for this real world schooling that it has been one helluva an eye opening experience. I also get where Matt is coming from on the shares lent out situation and how that may have impacted his strategies regarding the convertibles over the last couple of quarters. It must have been something for him to see how many in unison were joining in to lend out the shares thus making inventory more widely available. I imagine in the beginning it wasn't playing too big a role but as more and more joined in it must of most certainly caused some consternation on managements part when looking to implement different strategies for retiring the convertible. Bottom line the CC confirmed what my conversations have been with the SNY rep. and that is they continue to have a methodical plan in place both in dealing with the formulary issues and concurrently working within the medical professional arena to establish Afrezza for what it is and now has been endorsed by most of those using it... as a second to none best in class RAA insulin. I hear the swan song loud and clear and looking forward to the swan resting in peace as I smile now when I see those ads touting the inferior product ;) Maybe Novo is taking a play out of GM's book - sell at a loss and make it up on volume! Sarc off. If the only strategy is to cut prices then it implies the product is a commodity and in a world where innovation is critical to the health of a company, cutting price is hardly a viable long term strategy. So if health insurer A signs a deal with Novo and then is bought by health insurer B can the acquiring company demand the better price without any of the commitments made by Co A to Novo - hypothetical question and fun to ask. |
|
|
|
Post by tbone on Aug 10, 2015 11:28:02 GMT -5
Matt put to rest the FUD being spread on DaZoo (and briefly discussed here) that management is lending out shares, stating that MannKind employees are not allowed to keep their shares in any account that permits lending. Thanks for clearing that up, Matt! Employees. Is Al Mann considered an employee? Does he fall under that? I am a cynic so I was thinking both ways about the comment If Al were making his shares available then do you suppose there would be ANY demand (read interest offered) for additional shares? The fact that they are hard to borrow and command interest tells you Al's shares aren't available, no? |
|
|
|
Post by newmnkdinvestor on Aug 10, 2015 11:41:52 GMT -5
That's a good point. Can you pick and choose how much is lent out of your position?
I am not saying he is or isn't. I just cant help but always question things. Its the type of person I am.
|
|
|
|
Post by jpg on Aug 10, 2015 11:52:29 GMT -5
That's a good point. Can you pick and choose how much is lent out of your position? I am not saying he is or isn't. I just cant help but always question things. Its the type of person I am. Yeah Al Mann hates shorts. Wants his company to succeed but will lend them just enough shares to cripple Mannkind. And this wouldn't be material (reportable) info? Sounds rational to you? |
|
adh
Newbie
Posts: 12 
|
Post by adh on Aug 10, 2015 12:07:03 GMT -5
No position in MNKD just just following the saga. From what I understand from the comments of this board Matt asked Shareholders to not lend out their shares to shorts. Folks' very fundamentally there is one reason to buy stock and one reason to short a stock. You buy because you expect the stock to increase in price, you short a stock because you expect the stock price to decline. Matt is blaming poor PPS on Shorts, what a bunch of baloney! If Matt wants to increase PPS and decrease the short holdings how about pressuring SNY to do some real marketing, get the pricing competitive, get some insurance companies on board.... Matt should be ashamed of this cop-out and take ownership for the reasons of poor stock performance, there's a good reason why you've never heard shorts addressed in a conference call before, most presenters take accountability instead of blaming others. The following is an email that I sent to Matt this am: There is nothing we investors can do to turn the tide. The catalyst (s) that will turn the tide (i.e pps) will have to come from either Sanofi and/or Mankind. Great CC! VR/Austin Sent from my Verizon Wireless 4G LTE smartphone |
|
|
|
Post by newmnkdinvestor on Aug 10, 2015 12:13:34 GMT -5
That's a good point. Can you pick and choose how much is lent out of your position? I am not saying he is or isn't. I just cant help but always question things. Its the type of person I am. Yeah Al Mann hates shorts. Wants his company to succeed but will lend them just enough shares to cripple Mannkind. And this wouldn't be material (reportable) info? Sounds rational to you? No it sounds completely irrational once you pit it that way lol |
|
|
|
Post by hankscorpio7 on Aug 10, 2015 12:24:22 GMT -5
Haha- if only Matt said management and board can't lend. As much as one would find it hard to believe Dr. Mann would loan shares, unless posted, it can be speculated. Or is there really a 200m share "actual" float- of which 120m are short? Hard to imagine but possible. Maybe Matt is chumming the waters to attract bigger traders. 20 funds buy 10m each- shares go to $20- sell 5m each and shorts still have to cover. If that happens- would I be guilty of collusion?
Anyway, to blame loan programs for share price is ludicrous. When this company has quarterly PROFITS and a PE under 10, maybe there is manipulation. I mostly deal in options so have not loaned shares. Maybe he will blame the options market next quarter. If we bust with 50m short or 200m, we- being shareholders( or calls)are still bust. If we take off with 50m, not as sweet as 200m short. We need scripts- not stock loaners witch hunts .
|
|
|
|
Post by kc on Aug 10, 2015 12:31:48 GMT -5
If you have a Margin account you can still designate that your MannKind shares be held in a cash position and they should not be lent out. hmmm, I dont follow that. I thought margin is only added to a cash account as a perq for working with that broker. However the perq they receive is getting to lend out your shares and collect interest. In my cash account the amount I am able to margin is based on the value of my cash account. Your way sounds too good to be true. I just dont see why they would let you use their money and then let you avoid the shares being lent out. Essentially you could lend out your margined shares. I have MNKD shares in my margin account that are designated as cash shares. This is at Fidelity. |
|
Thus, the insulin wars have begun and as Matt stated, "they have some strategic efforts being worked on" when asked about the formulary issues. 
